GBT and Sickle Cell Disease Association of America to Host 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference
September 08, 2021 17:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA)...
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11
September 07, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
New Drug Application for Oxbryta dispersible tablets also accepted for priority review Approximately 17,000 children ages 4 to 11 years have sickle cell disease in the United States SOUTH SAN...
GBT Announces Participation in Upcoming Investor Conferences
September 02, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the...
GBT Announces New Employment Inducement Grants
August 12, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2021, the compensation committee of GBT’s board...
GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
August 04, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush...
GBT Reports Second Quarter 2021 Financial Results
August 03, 2021 16:05 ET
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $47.6 million, an increase of 51% year-over-year Continued progress toward potential Oxbryta pediatric label expansion in U.S. and marketing...
GBT to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
July 27, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2021 financial results on...
GBT Provides Regulatory and Pipeline Updates in Sickle Cell Disease (SCD)
July 22, 2021 07:00 ET
|
Global Blood Therapeutics, Inc.
Submits Supplemental New Drug Application to the U.S. FDA for Oxbryta® (voxelotor) in Children with SCD Ages 4 to 11 Initiates Phase 3 Clinical Trials of Inclacumab and Enrolls First SCD Patient in...
GBT Announces New Employment Inducement Grants
July 09, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2021, the compensation committee of GBT’s board of...
GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease
June 15, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) has awarded approximately $450,000 to U.S. community-based organizations and...